Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Blank, Christian U.; Larkin, James; Arance, Ana M.; Hauschild, Axel; Queirolo, Paola; Del Vecchio, Michele; Ascierto, Paolo A.; Krajsova, Ivana; Schachter, Jacob; Neyns, Bart; Garbe, Claus; Sileni, Vanna Chiarion; Mandala, Mario; Gogas, Helen; Espinosa, Enrique; Hospers, Geke A. P.; Miller, Wilson H., Jr.; Robson, Susan; Makrutzki, Martina; Antic, Vladan; Brown, Michael P.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

Autor(en):

Blank, Christian U.; Larkin, James; Arance, Ana M.; Hauschild, Axel; Queirolo, Paola; Del Vecchio, Michele; Ascierto, Paolo A.; Krajsova, Ivana; Schachter, Jacob; Neyns, Bart; Garbe, Claus; Sileni, Vanna Chiarion; Mandala, Mario; Gogas, Helen; Espinosa, Enrique; Hospers, Geke A. P.; Miller, Wilson H., Jr.; Robson, Susan; Makrutzki, Martina; Antic, Vladan; Brown, Michael P.

Tübinger Autor(en):

Garbe, Claus

Erschienen in:

European Journal of Cancer (2017), Bd. 79, S. 176-184

Verlagsangabe:

Elsevier Sci Ltd

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.ejca.2017.04.007

ISSN:

1879-0852